# US 2025/0017910 A1 · 2-Thioxothiazolidine-4-One Derivatives And Their Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017910 A1
- Document ID: US20250017910A1
- Status: Published application
- Kind: A1
- Application number: 18/760,472
- Filed: 2024-07-01
- Published: 2025-01-16
- Earliest claimed: 2023-06-29
- Applicants: Prosetta Biosciences, Inc.
- Inventors: Kumarapandian Paulvannan; Dennis Solas; Anuradha F. Lingappa; Vishwanath R. Lingappa
- Web page: https://patentgrep.com/patent/US20250017910A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/30: for treating abuse or dependence
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein are 2-thioxothiazolidine-4-one derivatives, and pharmaceutical compositions thereof. The 2-thioxothiazolidine-4-one derivatives and pharmaceutical compositions thereof may be used to treat or prevent medical disorders such as, for example, Parkinson's disease, and disorders of dopamine homeostasis, such as for example, methamphetamine and cocaine addiction.

## Claims

### Claim 1

A compound of structural formula:
or pharmaceutically acceptable salts, hydrate or solvates thereof wherein:
R1 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloheteroalkyl, substituted cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R2 is —H or alkyl;
n is 1 or 2;
X is —O— or —S—;
R3 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is alkyl, alkenyl, cycloheteroalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 3 (depends on 2)

The compound of claim 2 wherein R2 is —H.

### Claim 4 (depends on 2)

The compound of claim 2, wherein X is —O—.

### Claim 5 (depends on 2)

The compound of claim 2, wherein R3 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R1 is alkyl, alkenyl, cycloheteroalkyl, aryl, substituted aryl or heteroaryl; R2 is —H; X is —O—; and R3 is aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is phenyl or substituted phenyl and R3 is substituted phenyl.

### Claim 8 (depends on 6)

The compound of claim 6, wherein R1 is heteroaryl and R3 is substituted phenyl.

### Claim 9 (depends on 6)

The compound of claim 6, wherein R1 is alkyl and R3 is substituted phenyl.

### Claim 10 (depends on 6)

The compound of claim 6, wherein R1 is alkenyl and R3 is substituted phenyl.

### Claim 11 (depends on 6)

The compound of claim 6, wherein R1 is cycloheteroalkyl and R3 is substituted phenyl.

### Claim 12 (depends on 6)

The compound of claim 6, wherein R1 is heteroaryl or substituted heteroaryl, and R3 is substituted phenyl.

### Claim 13 (depends on 1)

The compound of claim 1 and a pharmaceutically acceptable vehicle.

### Claim 14 (depends on 1, 13)

A method of treating Parkinsons's disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 or the pharmaceutical composition of claim 13.

### Claim 15 (depends on 1, 13)

A method of treating methamphetamine addiction in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 or the pharmaceutical composition of claim 13.

### Claim 16 (depends on 1, 13)

A method of treating cocaine addiction in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 or the pharmaceutical composition of claim 13.

### Claim 17 (depends on 1, 13)

A method of treating disorders of dopamine homeostasis in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1 or the pharmaceutical composition of claim 13.
